Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Zacks.com on MSN5d
Vertex to Report Q4 Earnings: What's in Store for the Stock?Vertex, Inc. VERX is scheduled to report fourth-quarter 2024 results before market open on Feb. 27. Find the latest EPS ...
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...
Vertex, Inc. (VERX) has disclosed a new risk, in the Debt & Financing category. Vertex, Inc. faces significant financial risk in the event of a ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
The stock's rise snapped a four-day losing streak.
Vertex Inc (VERX) reports robust revenue growth and strategic investments in AI and e-invoicing, setting the stage for future expansion despite margin pressures. The headline numbers for Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback